Sare Verstockt

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/585234/publications.pdf

Version: 2024-02-01

933447 839539 25 660 10 18 citations h-index g-index papers 26 26 26 1014 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Genetic and Transcriptomic Bases of Intestinal Epithelial Barrier Dysfunction in Inflammatory Bowel Diseases. Inflammatory Bowel Diseases, 2017, 23, 1718-1729.	1.9	156
2	Low TREM1 expression in whole blood predicts anti-TNF response in inflammatory bowel disease. EBioMedicine, 2019, 40, 733-742.	6.1	119
3	Oncostatin M Is a Biomarker of Diagnosis, Worse Disease Prognosis, and Therapeutic Nonresponse in Inflammatory Bowel Disease. Inflammatory Bowel Diseases, 2021, 27, 1564-1575.	1.9	53
4	Mucosal IL13RA2 expression predicts nonresponse to anti‶NF therapy in Crohn's disease. Alimentary Pharmacology and Therapeutics, 2019, 49, 572-581.	3.7	52
5	Expression Levels of 4 Genes in Colon Tissue Might Be Used to Predict Which Patients Will Enter Endoscopic Remission After Vedolizumab Therapy for Inflammatory Bowel Diseases. Clinical Gastroenterology and Hepatology, 2020, 18, 1142-1151.e10.	4.4	50
6	TREM-1, the ideal predictive biomarker for endoscopic healing in anti-TNF-treated Crohn's disease patients?. Gut, 2019, 68, 1531-1533.	12.1	42
7	Gene and Mirna Regulatory Networks During Different Stages of Crohn's Disease. Journal of Crohn's and Colitis, 2019, 13, 916-930.	1.3	41
8	Oncostatin M as a new diagnostic, prognostic and therapeutic target in inflammatory bowel disease (IBD). Expert Opinion on Therapeutic Targets, 2019, 23, 943-954.	3.4	40
9	Intestinal Receptor of SARS-CoV-2 in Inflamed IBD Tissue Seems Downregulated by HNF4A in Ileum and Upregulated by Interferon Regulating Factors in Colon. Journal of Crohn's and Colitis, 2021, 15, 485-498.	1.3	34
10	Understanding the Molecular Drivers of Disease Heterogeneity in Crohn's Disease Using Multi-omic Data Integration and Network Analysis. Inflammatory Bowel Diseases, 2021, 27, 870-886.	1.9	24
11	Neutrophilic HGF-MET Signalling Exacerbates Intestinal Inflammation. Journal of Crohn's and Colitis, 2020, 14, 1748-1758.	1.3	12
12	Tailoring Multi-omics to Inflammatory Bowel Diseases: All for One and One for All. Journal of Crohn's and Colitis, 2022, 16, 1306-1320.	1.3	11
13	Microbiota, not host origin drives <i>ex vivo</i> intestinal epithelial responses. Gut Microbes, 2022, 14, .	9.8	8
14	Integrated analysis of microbe-host interactions in Crohn's disease reveals potential mechanisms of microbial proteins on host gene expression. IScience, 2022, 25, 103963.	4.1	7
15	Molecular Changes in the Non-Inflamed Terminal Ileum of Patients with Ulcerative Colitis. Cells, 2020, 9, 1793.	4.1	4
16	Inflammatory Bowel Disease (IBD)—A Textbook Case for Multi-Centric Banking of Human Biological Materials. Frontiers in Medicine, 2019, 6, 230.	2.6	3
17	Increased Baseline TNF-Driven Pathways Observed in Patients with Crohn's Disease not Responding to Infliximab. Gastroenterology, 2017, 152, S767.	1.3	2
18	Su1794 - Discrimination of Endoscopic Postoperative Recurrence in Patients with Crohn's Disease using Serological Inflammatory Markers. Gastroenterology, 2018, 154, S-586-S-587.	1.3	2

#	Article	IF	Citations
19	Molecular Profiling of Early Crohn's Disease Using the Post-Operative Recurrence Model. Gastroenterology, 2017, 152, S79-S80.	1.3	O
20	Tu1799 - Serum Proteomic Profiling Reveals Changes in Inflammatory Profiles with Consecutive Biological Therapies in Patients with Inflammatory Bowel Disease. Gastroenterology, 2018, 154, S-1023.	1.3	0
21	Sa1781 - Serological Markers Define Newly Diagnosed Crohn's Disease and Ulcerative Colitis Based on the age at Diagnosis. Gastroenterology, 2018, 154, S-392.	1.3	O
22	Tu1808 - Colonic Inflammation Determines Ileal Gene Expression Changes in Ulcerative Colitis. Gastroenterology, 2018, 154, S-1025-S-1026.	1.3	0
23	Tu1810 - Transcriptomic Profile of Inflamed Colonic Biopsies from Newly Diagnosed Crohn's Disease and Ulcerative Colitis Patients Depend on the age at Diagnosis. Gastroenterology, 2018, 154, S-1026.	1.3	O
24	1002 - Predictive Serological Markers of Response to Ustekinumab in Patients with Refractory Crohn's Provide Novel Insights in the Mechanism of Action. Gastroenterology, 2018, 154, S-187.	1.3	0
25	Mo1118 DEVELOPMENT OF AN EASY AND RAPID GENOTYPING ASSAY FOR THE VALIDATED IBD RISK LOCI. Gastroenterology, 2020, 158, S-793-S-794.	1.3	0